维利帕尼 T2591
品牌 | 厂商性质 | 产地 | 货期 |
---|---|---|---|
TargetMol | 生产商 | 美国 | 现货 |
性能特点
生化试剂,可用于动物细胞实验
规格 | CAS号 | 价格 | 操作 |
---|---|---|---|
1 mL | 912444-00-9 | ¥519.00 | 询底价 |
1 mg | 912444-00-9 | ¥209.00 | 询底价 |
500 mg | 912444-00-9 | ¥7,530.00 | 询底价 |
25 mg | 912444-00-9 | ¥1,180.00 | 询底价 |
100 mg | 912444-00-9 | ¥3,230.00 | 询底价 |
200 mg | 912444-00-9 | ¥4,770.00 | 询底价 |
10 mg | 912444-00-9 | ¥728.00 | 询底价 |
50 mg | 912444-00-9 | ¥1,730.00 | 询底价 |
5 mg | 912444-00-9 | ¥469.00 | 询底价 |
Product Introduction
Bioactivity
英文名: Veliparib
描述: Veliparib (ABT-888) 是一种可口服的 PARP 抑制剂,抑制PARP1和PARP2的Ki 分别为 5.2 和 2.9 nM。它增强细胞凋亡和自噬。
细胞实验: Cell viability was quantified using the Cell Counting Kit-8 (CCK-8). This assay is based on Dojindo's highly water-soluble tetrazolium salt. WST-8 is reduced by dehydrogenases in cells to give an orange, water-soluble formazan dye. The amount of formazan dye generated by dehydrogenases in cells is directly proportional to the number of living cells. Briefly, exponentially growing HaCaT cells were seeded in 96-well plates at a density of 10,000 cells/well. 6 h or 24 h after exposure to SM and the administration of ABT-888, the CCK-8 reagent was added as recommended by the supplier [2].
激酶实验: PARP assays were conducted in a buffer containing 50 mmol/L Tris (pH 8.0), 1 mmol/L DTT, 1.5 μmol/L [3H]NAD+ (1.6 μCi/mmol), 200 nmol/L biotinylated histone H1, 200 nmol/L slDNA, and 1 nmol/L PARP-1 or 4 nmol/L PARP-2 enzyme. Reactions were terminated with 1.5 mmol/L benzamide, transferred to streptavidin Flash plates, and counted using a TopCount microplate scintillation counter [1].
动物实验: For oral pharmacokinetic studies, ABT-888 was separated from plasma and brain homogenate using liquid-liquid extraction with a mixture of ethyl acetate and hexane at alkaline pH. ABT-888 and the internal standard were separated from each other and coextracted contaminants on a 50 × 3 mm Keystone Betasil Cyano 5 μm C18 column with acetonitrile: 0.1% trifluoroacetic acid mobile phase (40:60, by volume) at a flow rate of 0.3 mL/min. Analysis was done on a Sciex API3000 Biomolecular Mass Analyzer with a turbo-ionspray interface using Sciex MacQuan software. The analysis of plasma pharmacokinetics from osmotic minipump (OMP) studies was conducted using acidified methanol precipitated plasma. Samples were injected onto a Phenomenex Synergi 4μ Polar RP column and ABT-888 eluted with a mixture of acetonitrile and 0.1% acetic acid in water at a flow rate of 0.4 mL/min. Mass analysis was done with a ThermoFinnigan LCQ Duo using Xcalibur software [1].
体外活性: Veliparib (ABT-888) is a potent inhibitor of both PARP-1 and PARP-2 with K(i)s of 5.2 and 2.9 nmol/L, respectively [1]. In the HaCaT cell model, ABT-888 can reduce SM-induced NAD(+)/ATP depletion and apoptosis/necrosis [2]. ABT-888 reduced clonogenic survival in H460 lung cancer cells and inhibited DNA repair as shown by enhanced expression of DNA strand break marker histone gamma-H2AX [3].
体内活性: PARP inhibition dramatically increased the efficacy of temozolomide at ABT-888 doses as low as 3.1 mg/kg/d and a maximal efficacy achieved at 25 mg/kg/d. In the MX-1 breast xenograft model (BRCA1 deletion and BRCA2 mutation), ABT-888 potentiated cisplatin, carboplatin, and cyclophosphamide, causing regression of established tumors, whereas, with comparable doses of cytotoxic agents alone, only modest tumor inhibition was exhibited [1]. ABT-888 increased tumor growth delay at well-tolerated doses in murine models. For a 5-fold increase in tumor volume, tumor growth delay was 1 day for ABT-888 alone, 7 days for radiation alone, and 13.5 days for combination treatment. A decrease in vitro endothelial tubule formation with ABT-888/radiation combination treatment and von Willebrand factor staining of tumor sections revealed decreased vessel formation in vivo [3].
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: H2O : < 1 mg/mL (insoluble or slightly soluble)
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
DMSO : 29 mg/mL(118.7 mM)
关键字: Veliparib | inhibit | PARP | Inhibitor | ABT 888 | Autophagy | NSC737664 | poly ADP ribose polymerase | ABT888 | NSC-737664
相关产品: 1-[2,4-Dihydroxy-6-methoxy-3-(3-methyl-2-buten-1-yl)phenyl]-3-(4-hydroxyphenyl)-2-propen-1-one | KSQ-4279 | Buddlejasaponin IV | Lasiodin | Paris saponin VII | G244-LM | Talazoparib | Fluzoparib | NVP-TNKS656 | PARP14 inhibitor H10
相关库: Anti-Aging Compound Library | Drug Repurposing Compound Library | Anti-Prostate Cancer Compound Library | Anti-Breast Cancer Compound Library | Anti-Cancer Drug Library | Anti-Cancer Clinical Compound Library | Inhibitor Library | Highly Selective Inhibitor Library | Anti-Cancer Active Compound Library | Apoptosis Compound Library
维利帕尼 T2591信息由TargetMol中国为您提供,如您想了解更多关于维利帕尼 T2591报价、型号、参数等信息,欢迎来电或留言咨询。
注:该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案,不可用于临床诊断或治疗等相关用途